Status | Study |
Active, not recruiting |
Study Name: Red Cell Transfusion Goals in Patients With Acute Leukemias Condition: Acute Lymphoblastic Leukemia Acute Lymphocytic Leukemia (ALL) Date: 2014-03-04 Interventions: Procedure: RBC Transfusion: restrictive threshold (7 g/dL Hb) |
Enrolling by invitation |
Study Name: A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia Condition: Childhood Acute Promyelocytic Leukemia Date: 2014-02-08 Interventions: Drug: ATO Given IV |
Recruiting |
Study Name: Proteasome Inhibition in Acute Promyelocytic Leukemia Condition: Relapsed Acute Promyelocytic Leukemia Date: 2013-09-22 Interventions: Drug: Bortezomib Combination of arsenic trioxide with bortezomib in the treatment of relapsed acute prom |
Active, not recruiting |
Study Name: A Safety Study of SGN-CD33A in AML Patients Condition: Acute Myelogenous Leukemia Acute Myeloid Leukemia Date: 2013-07-15 Interventions: Drug: HMA azacitidine 75 mg/m2 |
Suspended |
Study Name: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia Condition: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia Wit Date: 2013-05-31 Interventions: Drug: gemtuzumab ozogamicin Gi |
Completed |
Study Name: Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia Condition: Acute Promyelocytic Leukemia Date: 2013-03-28 Interventions: Other: Health Related Quality of Life (HRQOL) measures Other Names: SF- |
Recruiting |
Study Name: Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL Condition: Acute Promyelocytic Leukemia Date: 2012-12-06 Interventions: Drug: ATRA+arsenic experimenta |
Active, not recruiting |
Study Name: Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Condition: Acute Leukemia of Ambiguous Lineage Adult Acute Myeloid Leukemia in Remission Date: 2012-10-03 Interventions: Drug: Cytarabine Given IV |
Active, not recruiting |
Study Name: Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Condition: Accelerated Phase Chronic Myelogenous Leukemia Adult Acute Lymphoblastic Leukemia in Remissi Date: 2012-04-26 Interventions: Biological: tetanus-CMV fusion peptide vaccine |
Withdrawn |
Study Name: Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia Condition: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia Wit Date: 2012-02-14 Interventions: Drug: gemtuzumab ozogamicin Gi |